A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance

Leukemia Research

Volumn 22, Issue 8, 1998, Pages 719-725

  Andrivon, William ^a   Monneret, Claude ^b   Nafziger, Joëlle ^a   Florent, Jean Claude ^b   Guillosson, Jean Jacques ^a  

^a UFR des Sciences Pharmaceutiques et Biologiques   (France)

^b INSTITUT CURIE   (France)

Author keywords

Cellular efflux; Cellular uptake; Multidrug resistance; New anthracycline derivative; P glycoprotein (P gp 170)

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; DAUNORUBICIN; DOXORUBICIN; GLYCOPROTEIN P; MOFLOMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

ARTICLE; CELL STRAIN HL 60; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HL-60 CELLS; HUMANS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0031843229     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00067-8     Document Type: Article

References (20)

1. Florent J.C., Genot A., Monneret C. Synthesis and anti-tumor activity of new anthracyclines. J Antibiot. 12:1989;1823.
2. Nafziger J., Auclair C., Florent J.C., Guillosson J.J., Monneret C. Pharmacological and physicochemical properties of a new anthracycline with potent anti-leukemic activity. Leuk Res. 15:1991;709.
3. Andrivon W., Saucier J.M., Auclair C., Monneret C., Florent J.C., Guillosson J.J., Nafziger J. Enhanced topoisomerase II-induced DNA breaks and free radical production by a new anthracycline with potent anti-leukemic activity. Leuk Res. 20:1996;119.
4. Andrivon W., Callais F., Nafziger J., Monneret C., Guillosson J.J. A new anthracycline with potent anti-leukemic activity exhibits reduced mutagenicity. Mutat Res. 34:1995;135.
5. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 58:1989;137.
6. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 455:1976;152.
7. Arceci R.J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood. 81:1993;2215.
8. Haber D.A. Multidrug resistance (MDR) in leukemia: Is it time to test? Blood. 7:1992;295.
9. Gerlach J.H., Kartner N., Bell D.R., Ling V. Multidrug resistance. Cancer Surv. 5:1986;25.
10. Booser D.J., Hortobagyi G.N. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs. 47:1994;223.
11. Schecter R.L., Alaoui-Jamalima M.A., Batist G. Glutathione S-transferase in chemotherapy resistance and in carcinogenesis. Biochem Cell Biol. 70:1992;349.
12. Samuels B.L., Murray J.L., Cohen M.B., Safa A.R., Sinha B.K., Townsend A.J., Beckett M.A., Weichselbaum R.R. Increased glutathione peroxydase activity in a human sarcoma cell line with inherent doxorubicin resistance. Cancer Res. 51:1991;521.
13. Beck W.T., Danks M.K. Multidrug resistance associated with alterations in topoisomerase II. Potmesil M., Kohn K. The Second Conference on DNA Topoisomerase in Therapy. 1991;260 Oxford University Press, Oxford.
14. Lehnert M., Dalton W.S., Roe D., Emerson S., Salmon S.E. Synergistic inhibition by verapamil and quinine of P-glycoprotein mediated multidrug resistance in a human myeloma cell line model. Blood. 77:1991;348.
15. Maruyama Y., Murohashi I., Nara N., Aoki N. Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukemic blast progenitors in acute myelogenous leukemia. Br J Haematol. 72:1989;357.
16. Borenfreund D., Puerner A. A simple quantitative procedure using monolayer culture for cytotoxicity assay (HTD/NR90). J Tissue Cult Methods. 9:1984;7.
17. Krishan A., Ganapathi R. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines. Cancer Res. 40:1980;3895.
18. Kartner N., Evernden-Porelle D., Bradley G., Ling V. Detection of P-glycoprotein in multidrug resistant cell lines by monoclonal antibodies. Nature. 316:1984;820.
19. Priebe W., Van N.T., Burke T.H., Perez-Soler R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anti-Cancer Drugs. 4:1993;37.
20. Priebe W., Perez-Soler R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach. Pharmacol Ther. 60:1993;215.